INTELLIA THERAPEUTICS INC (NTLA) Stock Income Statement
NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.57M | 57.88M | 36.27M | 52.12M | 33.05M | |||
| Operating Expenses | 586.64M | 592.14M | 551.57M | 510.29M | 300.90M | |||
| Research and Development | 462.89M | 466.31M | 435.07M | 419.98M | 229.81M | |||
| Selling, General, and Administrative Expenses | 123.75M | 125.83M | 116.50M | 90.31M | 71.10M | |||
| Operating Income | -541.07M | -534.26M | -515.29M | -458.16M | -267.85M | |||
| Interest Income/Expense | 15.15M | 15.24M | 34.20M | -2.54M | -40.00K | |||
| Other Income/Expense | N/A | 0.00 | -100.00K | -13.49M | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -525.91M | -519.02M | -481.19M | -474.19M | -267.89M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -525.91M | -519.02M | -481.19M | -474.19M | -267.89M | |||
| EBITDA | -530.80M | -523.98M | -506.32M | -450.59M | -260.96M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -5.23 | -5.25 | -5.42 | -6.16 | -3.78 | |||
| Non GAAP EPS | -5.23 | -5.25 | -5.41 | -6.18 | -3.76 | |||
| Statistics | ||||||||
| Profit Margin | -1154.10% | -896.77% | -1326.51% | -909.80% | -810.56% | |||
| Operating Profit Margin | -1187.36% | -923.10% | -1420.51% | -879.05% | -810.44% | |||
All data in USD